

## REMARKS

Applicants respond to the Office Action dated November 21, 2008, for which a one month period of response is given.

### Sequence Listing

The attached substitute Sequence Listing has been amended as required by 37 C.F.R. §1.821(c) and 37 C.F.R. §§1.822-1.823 to include sequence identifiers for the sequences listed in original claims 3 and 4, and to correct errors in the listing of SEQ ID NOs 3-8, which are correctly listed in Table 1. Claims 3 and 4 have been amended to include a reference to the assigned identifier, as required in 37 C.F.R. §1.821(d).

A copy of the Sequence Listing is submitted herewith via EFS-Web. The content of the Sequence Listing is the same as that of the substitute paper Sequence Listing submitted herewith, and neither contains new matter.

### Restriction Requirement

The Examiner has required Applicants to elect a single invention to which the claims will be restricted from the following:

- Group I: drawn to a polypeptide comprising SEQ ID NO 1;
- Group II: drawn to a polypeptide comprising SEQ ID NO 2;
- Group III: drawn to a polypeptide comprising SEQ ID NO 3;
- Group IV: drawn to a polypeptide comprising SEQ ID NO 4;
- Group V: drawn to a polypeptide comprising SEQ ID NO 5;
- Group VI: drawn to a polypeptide comprising SEQ ID NO 9;
- Group VII: drawn to a polypeptide comprising SEQ ID NO 10;
- Group VIII: drawn to a polypeptide comprising SEQ ID NO 11;
- Group IX: drawn to a nucleic acid, vector and host cell.

In response to the restriction requirement, Applicants elect Group I. Claims 1-17 and 21-26 encompass a polypeptide comprising SEQ ID No 1.

The Examiner has stated that claim 1 links the inventions of Groups I-VIII and that upon the indication of allowability of the linking claim, the restriction requirement as to the linked inventions shall be withdrawn and any claims depending from or otherwise requiring all the limitations of the allowable linking claims will be rejoined and fully examined for patentability in accordance with 37 C.F.R. §1.104.

If any additional fees are required for the filing of this paper, the Commissioner is authorized to charge those fees to Deposit Account No. 18-0988 (Docket No. SPSUP0100WOUS).

Respectfully submitted,

RENNER, OTTO, BOISSELLE & SKLAR, LLP

By /Heidi A. Boehlefeld/  
Heidi A. Boehlefeld, Reg. No. 34,296

1621 Euclid Avenue  
Nineteenth Floor  
Cleveland, Ohio 44115  
(216) 621-1113